BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AMG 691 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AMG 691\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07745907-3967@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:AMG 691: Phase 1 readout est. (NCT07745907)
DESCRIPTION:AMG 691\, phase 1.\nStudy: A Phase 1 Trial of AMG 691 in Health
 y Chinese and Japanese Volunteers\nEstimated primary completion: 17 March 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/amg-691#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07745907
URL:https://assetmemo.bio/drug/amg-691#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06637371-3967@assetmemo.bio
DTSTAMP:20261121T005711Z
DTSTART;VALUE=DATE:20270410
DTEND;VALUE=DATE:20270411
SUMMARY:AMG 691: Phase 1 readout est. (NCT06637371)
DESCRIPTION:AMG 691\, phase 1\, Asthma.\nStudy: A Phase 1\, Randomized\, Do
 uble-blind\, Placebo-controlled Study Evaluating AMG 691 in Healthy Partic
 ipants and Participants With Mild-to-Moderate Asthma\nEstimated primary co
 mpletion: 10 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/amg-691#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06637371
URL:https://assetmemo.bio/drug/amg-691#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
